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Etanercept (Amgen Inc, Thousand Oaks, CA) is a human soluble p75 tumor necrosis factor (TNF) receptor-
human-IgG1 (hup75 TNFR-huIgG1) fusion protein used in the treatment of chronic inflammatory diseases in
humans, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis,
and psoriasis. To be able to study the effects of the soluble receptor fusion protein in mouse models, including
those that mimic human granulomatous infections, a murine soluble p75-TNF receptor-murine IgG1 (murine
p75-murine IgG1) fusion protein had to be constructed. This article discusses the generation, large-scale
production, and purification of this molecule.
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RESULTS AND DISCUSSION
Etanercept is a human p75 tumor necrosis factor (TNF)
soluble receptor-IgG1 (hup75-TNFR-huIgG1) fusion protein
used in the treatment of chronic inflammatory diseases in
humans. Clinical evidence that the safety and efficacy
profiles of this TNF antagonist appear to differ from those
of the anti-TNF antibodies has prompted investigators to
want to study the mechanism of action of this soluble
receptor in animal models. The generation, large-scale
production, and purification of the murine p75-murine
IgG1 fusion protein provided a molecule that can be used
to study the effects of the TNF soluble receptor fusion protein
in mouse models, including those that mimic human
granulomatous infections.
MATERIALS AND METHODS
Generation of the murine p75 (1–257)-murine IgG1 fusion
protein
Stable expression of the murine p75 (met1-gly257)-murine IgG1
fusion protein was achieved by transfection of AM-1/cyclin D
Chinese hamster ovary (AM-1/D CHO) cells (US patent #6,210,924)
with the expression vector pDSRa22 (Amgen Inc, Thousand Oaks,
CA). Transfection was performed using LipofectamineTM 2000
(LF2000) Reagent (Invitrogen Corporation, Carlsbad, CA) according
to the manufacturer’s suggestions. Briefly, 4 106 AM-1/D CHO
cells were plated 24 hours before transfection in 100-mm diameter
plastic BD-FalconTM Petri dishes (BD Biosciences, Bedford, MA) in
10 ml of DMEM, Invitrogen) supplemented with 5% fetal bovine
serum, 1 penicillin–streptomycin, and glutamine (Invitrogen), non-
essential amino acids (Invitrogen), sodium pyruvate, and sodium
hypoxanthine/thymidine supplement (Invitrogen). Approximately
30 mg of each pDSRa22-murine p75 (1–257)-murine IgG1Fc plasmid
DNA was linearized using the restriction enzyme Pvu I (New
England Biolabs Inc., Ipswich, MA) and diluted in 2 ml of OptiMEM
(Invitrogen). The diluted DNAs were mixed with 75 ml of LF2000
diluted in 2 ml of OptiMEM, and the mixture was incubated for
20 minutes at room temperature. The DNA–LF2000 mixture was
added to the cells and incubated overnight for transfection. The
following day, fresh growth medium was added and cells were
cultured for 48 hours at 371C with 5% CO2, and then plated in
hypoxanthine/thymidine selection medium at 1:20 and 1:50 dilu-
tions. Approximately 2 weeks after transfection, 12–24 visible
colonies were picked into 24-well plates, using sterile cloning discs
(Research Products International Corp., Mt Prospect, IL). The clones
expressing the highest level of murine p75 (1–257)-murine IgG1 Fc
were identified by Western immunoblot analysis (Towbin et al.,
1979; Burnette, 1981). To perform this assay, 0.5 ml of serum-free
medium was added to a single well of confluent cells cultured in a
BD-FalconTM 24-well plate (BD Biosciences). The conditioned
medium was recovered after 24 hours, and 10ml of it was mixed
with an equal volume of loading buffer and electrophoresed on a
10% Novexs Tris-Glycine polyacrylamide gel (Invitrogen).
The gel was transferred to a 0.45 mm pore size nitrocellulose
membrane (Invitrogen), and a Western Blot analysis was performed
using a 1:1,000 dilution of rabbit antimouse IgG Fc ImmunoPure
antibody labeled with horseradish peroxidase (Pierce Biotechnology
Inc., Rockford, IL) and enhanced chemiluminescence as a detection
agent. Clonal cells expressing the highest levels of the murine p75
(1–257)-murine IgG1 protein were expanded in BD-FalconTM T-175
tissue culture flasks (BD Biosciences) for subsequent scale-up.
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Large-scale expansion of the murine p75 (1–257)-murine IgG1
fusion protein
Approximately 2–3 107 cells were used to seed one Cornings
CellBINDs 850 cm2 polystyrene roller bottle (Corning Incorporated,
Corning, NY), and cells were subsequently expanded 1:10. Each
roller bottle was inoculated with 250 ml of high-glucose DMEM,
10% dialyzed fetal bovine serum, 1 glutamine, 1 non-essential
amino acids, and 1 sodium pyruvate (all from Invitrogen). Ten
percent CO2/balance air was bubbled into the medium for
2–3 seconds before each roller bottle was capped. Roller bottles
were incubated at 371C on roller racks spinning at 0.75 revolutions
per minute (r.p.m.).
When the cells were approximately 85–90% confluent (after
approximately 5–6 days in culture), the growth medium was
discarded, and the cells were washed with 100 ml phosphate-
buffered saline and 200 ml production medium, consisting of 50%
DMEM/50% Ham’s F12, 1 glutamine, 1 non-essential amino
acids, 1 sodium pyruvate (all from Invitrogen), and 1.5% dimethyl
sulfoxide (Sigma-Aldrich, St Louis, MO). The conditioned medium
containing murine p75 (1–257)-murine IgG1 was harvested every 7
days and then filtered through a 0.45/0.1 mm cellulose acetate filter
(Corning Incorporated).
Purification and properties of the murine p75-murine IgG1
fusion protein
Approximately 100 l of the conditioned medium containing murine
p75-murine IgG1 were concentrated using a 10 ft2 YM10 Amicon
spiral filter (Millipore, Bedford, MA). The concentrated material was
diluted 1:1 with a buffer containing 1 M glycine and 3 M KCl, pH 9.0,
then applied onto a chromatography column packed with 200 ml
MabSelectTM Media (GE Healthcare, Waukesha, WI) which had been
equilibrated with a buffer containing 500 mM glycine and 1.5 M KCl,
pH 9.0. After washing the column with the equilibration buffer until
the absorbance at 280 nm (OD280) was less than 0.1, the bound
protein was eluted with 0.1 M glycine-HCl, pH 2.7, and immediately
neutralized with 1 M Tris-HCl, pH 8.5. The neutralized eluted pool
was adjusted to pH 7.0 with sodium phosphate (10 mM), and then
ammonium sulfate was added to a final concentration of 1.5 M, pH
7.0. This material was applied onto a chromatography column
packed with 100 ml butyl sepharose (GE Healthcare) that had been
equilibrated with a buffer containing 10 mM sodium phosphate and
1.5 M ammonium sulfate, pH 7.0. The protein was eluted with a
linear gradient of 1.5 to 0 M ammonium sulfate, pH 7.0, over 75
column volumes. The fractions containing murine p75-murine IgG1
were pooled and dialyzed against 4 l phosphate-buffered saline for
20 hours at 41C with four buffer changes.
Approximately 2.5 g of murine p75-murine IgG1 were purified
from the 100 l of conditioned medium. The endotoxin level,
measured using the EndosafeTM system (Charles River Lab, Wilming-
ton, MA) was less than 1 EU/mg of protein. The bioactivity of the
protein was determined by using the muTNF-sensitive mouse
fibroblast cell line L929 (American Type Culture Collection,
Manassas, VA) as described by Matthews and Neale (1987). The
assay showed the molar concentration that produces 50% of the
maximum possible inhibitory response (IC50) to be approximately
0.34 nM when 91rM of muTNF was used. Using the KinExA method
(Sapidyne Instruments Inc., Boise, ID), the equilibrium constant for
dissociation (Kd) was measured to be approximately 15 rM. Biacore
s
analysis (Biacore AB, Uppsala, Sweden) indicated that murine p75-
murine IgG1 has a fast reverse rate constant (koff) (approximately
4.8 104 seconds1). It has a half-life of 105 hours (4.5 days) in
mice, and simulation of the pharmacokinetic analyses showed that a
5 mg/kg once weekly dose (administered through an intravenous,
subcutaneous, or intraperitoneal route) should maintain a plasma
concentration of more than 100 nM (10 mg/ml).
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